SB And LG Chemical In Antibiotic Deal
- SmithKline Beecham has signed a worldwide development and marketingagreement with LG Chemical of Korea for LB20304a, a new broad-spectrum antibiotic. The antibiotic has already completed Phase I testing in Europe, and is active in vitro against all important respiratory pathogens tested to date. It "has the potential to become the once-daily drug of choice for the treatment of respiratory infections," said SB. LG Chem retains Korean rights. Meantime, SB has also licensed marketing rights to tranilast, an antiproliferative agent awaiting approval in Japan for the prevention of restenosis after angioplasty, from Kissei Pharmaceutical. SB has worldwide rights to the drug outside Japan, China, Taiwan, Korea and Russia. The drug is given orally for three months after the procedure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze